ClindaCure

Manufacturer
VEDCO | FIRST PRIORITY INCORPORATED
Effective date
2024-12-09
Label type
PRESCRIPTION ANIMAL DRUG LABEL
Version
11
Source
full-release
Hydrated at
2026-06-01 02:43:57

Label at a glance#

ProductClindaCure
Active ingredientCLINDAMYCIN HYDROCHLORIDE
Label structure15 sections

Dosage and administration

Dogs: Infected Wounds, Abscesses and Dental Infections Oral: 2.5 - 15.0 mg/lb body weight every 12 hours. Duration: Treatment with Clindamycin Hydrochloride Oral Drops products may be continued up to a maximum of 28 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three or four days if no response to therapy is seen. Dosage Schedule: Oral Solution Clindamycin...

Storage and handling

Store at controlled room temperature between 20° to 25° C (68° to 77° F) [see USP]. Keep container tightly closed when not in use. Rev. 10-22 Distributed By: VEDCO, INC. St. Joseph, MO 64507

Label contents#

Full prescribing information#

WARNINGS AND PRECAUTIONS SECTION

Approved for use in dogs and cats.

Equivalent to 25 mg/mL clindamycin

NET CONTENTS: 20 mL (0.68 fl oz)

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Not For Use in Humans
Keep Out of Reach of Children

DESCRIPTION

DESCRIPTION SECTION

Clindamycin Hydrochloride Oral Drops (clindamycin hydrochloride liquid) contains clindamycin hydrochloride which is the hydrated salt of clindamycin. Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chlorosubstitution of the 7(R)-hydroxyl group of a naturally produced antibiotic produced by Streptomyces lincolnensis var. lincolnensis.

Clindamycin Hydrochloride Oral Drops (For Use in Dogs and Cats) is a palatable formulation intended for oral administration. Each mL of Clindamycin Hydrochloride Oral Drops contains clindamycin hydrochloride equivalent to 25 mg clindamycin; and ethyl alcohol, 8.64%.

INDICATIONS

INDICATIONS & USAGE SECTION

Clindamycin Hydrochloride Oral Drops (for use in dogs and cats) is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below:

DOGS:

USE IN SPECIFIC POPULATIONS SECTION

Skin infections(wounds and abscesses) due to coagulase positive staphylococci (Staphylococcus aureus or Staphylococcus intermedius). Deep wounds and abscesses due to Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens. Dental infections due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens. Osteomyelitis due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.

CATS:

USE IN SPECIFIC POPULATIONS SECTION

Skin infections (wounds and abscesses) due to Staphylococcus aureus, Staphylococcus intermedius and Streptococcus spp. Deep wounds and infections due to Clostridium perfringens and Bacteroides fragilis. Dental infections due to Staphylococcus aureus, Staphylococcus intermedius, Streptococcus spp., Clostridium perfringens and Bacteroides fragilis.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Dogs:

Infected Wounds, Abscesses and Dental Infections

Oral: 2.5 - 15.0 mg/lb body weight every 12 hours.

Duration: Treatment with Clindamycin Hydrochloride Oral Drops products may be continued up to a maximum of 28 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three or four days if no response to therapy is seen.

Dosage Schedule:

Oral Solution

Clindamycin Hydrochloride Oral Drops, administer 1-6 mL/10 lbs body weight every 12 hours.

Dogs:

Osteomyelitis

Oral: 5.0-15.0 mg/lb body weight every 12 hours.

Duration: Treatment with Clindamycin Hydrochloride Oral Drops is recommended for a minimum of 28 days. Treatment should not be continued for longer than 28 days if no response to therapy is seen.

Dosage Schedule:

Oral Solution

Clindamycin Hydrochloride Oral Drops, administer 2-6 mL/10 lbs body weight every 12 hours.

Cats:

Infected Wounds, Abscesses and Dental Infections

5.0 - 15.0 mg/lb body weight once every 24 hours depending on the severity of the condition.

Duration: Treatment with Clindamycin Hydrochloride Oral Drops may be continued up to a maximum of 14 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three to four days if no clinical response to therapy is seen.

Dosage Schedule:

Clindamycin Hydrochloride Oral Drops, to provide 5.0 mg/lb, administer 1 mL/5 lbs body weight once every 24 hours; to provide 15.0 mg/lb, administer 3 mL/5 lbs body weight once every 24 hours.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Clindamycin Hydrochloride Oral Drops is contraindicated in animals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

Because of potential adverse gastrointestinal effects, do not administer to rabbits, hamsters, guinea pigs, horses, chinchillas or ruminating animals.

WARNINGS

WARNINGS SECTION

Not for use in humans. Keep out of reach of children. To obtain a Safety Data Sheet(s), contact Vedco, Inc. at (888) 708-3326 or www.vedco.com. Keep ClindaCure® in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

PRECAUTIONS

PRECAUTIONS SECTION

During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed.

The use of Clindamycin Hydrochloride Oral Drops occasionally results in overgrowth of non-susceptible organisms such as clostridia and yeasts. Therefore, the administration of Clindamycin Hydrochloride Oral Drops should be avoided in those species sensitive to the gastrointestinal effects of clindamycin (see CONTRAINDICATIONS). Should superinfections occur, appropriate measures should be taken as indicated by the clinical situation.

Patients with very severe renal disease and/or very severe hepatic disease accompanied by severe metabolic aberrations should be dosed with caution, and serum clindamycin levels monitored during high-dose therapy.

Clindamycin hydrochloride has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, Clindamycin Hydrochloride Oral Drops should be used with caution in animals receiving such agents.

Safety in gestating bitches and queens or breeding male dogs and cats has not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Side effects occasionally observed in either clinical trials or during clinical use were vomiting and diarrhea.

To report a suspected adverse reaction or to request a material safety data sheet (MSDS), call (888) 708-3326.

ACTIONS

MECHANISM OF ACTION SECTION

Site and Mode of Action: Clindamycin is an inhibitor of protein synthesis in the bacterial cell. The site of binding appears to be in the 50S sub-unit of the ribosome. Binding occurs to the soluble RNA fraction of certain ribosomes, thereby inhibiting the binding of amino acids to those ribosomes. Clindamycin differs from cell wall inhibitors in that it causes irreversible modification of the protein- synthesizing subcellular elements at the ribosomal level.

MICROBIOLOGY SECTION

Microbiology: Clindamycin is a lincosaminide antimicrobial agent with activity against a wide variety of aerobic and anaerobic bacterial pathogens. Clindamycin is a bacteriostatic compound that inhibits bacterial protein synthesis by binding to the 50S ribosomal sub-unit. The minimum inhibitory concentrations (MICs) of Gram-positive and obligate anaerobic pathogens isolated from dogs and cats in the United States are presented in Table 1 and Table 2. Bacteria were isolated in 1998-1999. All MICs were performed in accordance with the National Committee for Clinical Laboratory Standards (NCCLS).

LABORATORY TESTS SECTION
Table 1. Clindamycin MIC Values (ug/mL) from Diagnostic Laboratory Survey Data Evaluating Canine Pathogens in the U.S. During 1998-991
 Organism

 Number of

Isolates

 MIC50  MIC85  MIC90  Range
 Soft Tissue/Wound2
Staphylococcus aureus 17 0.5 0.5>4.0 0.25->4.0
Staphylococcus intermedius 28 0.25 0.5>4.0 0.125->4.0
Staphylococcus spp. 18 0.5 0.5>4.0 0.25->4.0
   Beta-hemolytic streptococci 46 0.5 0.5>4.0 0.25->4.0
Streptococcus spp. 11 0.5>4.0>4.0 0.25->4.0
 Osteomyelitis/Bone3
Staphylococcus aureus 20 0.5 0.5 0.5 0.54
Staphylococcus intermedius 15 0.5>4.0>4.0 0.25->4.0
Staphylococcus spp. 18 0.5>4.0>4.0 0.25->4.0
   Beta-hemolytic streptococci 21 0.5 2.0 2.0 0.25->4.0
Streptococcus spp. 21>4.0>4.0>4.0 0.25->4.0
 Dermal/Skin5
Staphylococcus aureus 25 0.5>4.0>4.0 0.25->4.0
Staphylococcus intermedius 48 0.5>4.0>4.0 0.125->4.0
Staphlyococcus spp. 32 0.5>4.0>4.0 0.25->4.0
   Beta-hemolytic streptococci 17 0.5 0.5 0.5 0.25-0.5

1 The correlation between the in vitro susceptibility data and clinical response has not been determined.

2 Soft Tissue/Wound: includes samples labeled wound, abscess, aspirate, exudates, draining tract, lesion, and mass

3 Osteomyelitis/Bone: includes samples labeled bone, fracture, joint, tendon

4 No range, all isolates yielded the same value

5 Dermal/Skin: includes samples labeled skin, skin swab, biopsy, incision, lip

LABORATORY TESTS SECTION
Table 2. Clindamycin MIC Values (ug/mL) from Diagnostic Laboratory Survey Data Evaluating Feline Pathogens from Wound and Abscess Samples in the U.S. During 19981
 Organism

 Number of

Isolates

 MIC50  MIC90  Range
Bacteroides/Prevotella 30 0.06 4.0<0.015-4.0
Fusobacterium spp. 17 0.25 0.25<0.015-0.5
Peptostreptococcus spp. 18 0.13 0.5<0.015-8.0
Porphyromonas spp. 13 0.06 0.25<0.015-8.0

1 The correlation between the in vitro susceptibility data and clinical response has not been determined.

PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Absorption: Clindamycin hydrochloride is rapidly absorbed from the canine and feline gastrointestinal tract.

Dog Serum Levels:

CLINICAL STUDIES SECTION

image of dog serum levelimage of dog serum level

Serum levels at or above 0.5 μg/mL can be maintained by oral dosing at a rate of 5.0 mg/lb of clindamycin hydrochloride every 12 hours. This same study revealed that average peak serum concentrations of clindamycin occur 1 hour and 15 minutes after oral dosing. The elimination half-life for clindamycin in dog serum was approximately 5 hours. There was no bioactivity accumulation after a regimen of multiple oral doses in healthy dogs.

Cat Serum Levels:

CLINICAL STUDIES SECTION

image of cat serum levelimage of cat serum level

Serum levels at or above 0.5 μg/mL can be maintained by oral dosing at a rate of 5.0 mg/lb of clindamycin hydrochloride every 24 hours. The average peak serum concentration of clindamycin occurs approximately 1 hour after oral dosing. The elimination half-life of clindamycin in feline serum is approximately 7.5 hours. In healthy cats, minimal accumulation occurs after multiple oral doses of clindamycin hydrochloride, and steady-state should be achieved by the third dose.

METABOLISM AND EXCRETION

INFORMATION FOR OWNERS/CAREGIVERS SECTION

Extensive studies of the metabolism and excretion of clindamycin hydrochloride administered orally in animals and humans have shown that unchanged drug and bioactive and bioinactive metabolites are excreted in urine and feces. Almost all of the bioactivity detected in serum after Clindamycin Hydrochloride Oral Drops product administration is due to the parent molecule (clindamycin). Urine bioactivity, however, reflects a mixture of clindamycin and active metabolites, especially N-demethyl clindamycin and clindamycin sulfoxide.

ANIMAL SAFETY SUMMARY

ANIMAL PHARMACOLOGY & OR TOXICOLOGY SECTION

Rat and Dog Data: One year oral toxicity studies in rats and dogs at doses of 30, 100 and 300 mg/kg/day (13.6, 45.5 and 136.4 mg/lb/day) have shown clindamycin hydrochloride to be well tolerated. Differences did not occur in the parameters evaluated to assess toxicity when comparing groups of treated animals with contemporary controls. Rats administered clindamycin hydrochloride at 600 mg/kg/day (272.7 mg/lb/day) for six months tolerated the drug well; however, dogs orally dosed at 600 mg/kg/day (272.7 mg/lb/day) vomited, had anorexia, and subsequently lost weight. At necropsy these dogs had erosive gastritis and focal areas of necrosis of the mucosa of the gallbladder.

Safety in gestating bitches or breeding males has not been established.

ANIMAL SAFETY SUMMARY

ANIMAL PHARMACOLOGY & OR TOXICOLOGY SECTION

Cat Data: The recommended daily therapeutic dose range for clindamycin hydrochloride (Clindamycin Hydrochloride Oral Drops) is 11 to 33 mg/kg/day (5 to 15 mg/lb/day) depending on the severity of the condition. Clindamycin hydrochloride (Clindamycin Hydrochloride Oral Drops) was tolerated with little evidence of toxicity in domestic shorthair cats when administered orally at 10x the minimum recommended therapeutic daily dose (11 mg/kg; 5 mg/lb) for 15 days, and at doses up to 5x the minimum recommended therapeutic dose for 42 days.

Gastrointestinal tract upset (soft feces to diarrhea) occurred in control and treated cats with emesis occurring at doses 3x or greater than the minimum recommended therapeutic dose (11 mg/kg/day; 5 mg/lb/day). Lymphocytic inflammation of the gallbladder was noted in a greater number of treated cats at the 110 mg/kg/day (50 mg/lb/day) dose level than for control cats. No other effects were noted. Safety in gestating queens or breeding male cats has not been established.

HOW SUPPLIED

HOW SUPPLIED SECTION

ClindaCure® is available as 20 mL filled in 30 mL bottles (25 mg/mL) supplied in packers containing 12 cartoned bottles with direction labels and calibrated dosing droppers.

STORAGE

STORAGE AND HANDLING SECTION

Store at controlled room temperature between 20° to 25° C (68° to 77° F) [see USP].

Keep container tightly closed when not in use.

Rev. 10-22

Distributed By:
VEDCO, INC.
St. Joseph, MO 64507

20 mL label rev. 09-24

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

20 mL bottle/case label20 mL bottle/case label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Image of carton labelImage of carton label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1085918ClindaCure 25 MG in 1 mL Oral SolutionPSN11
900424clindamycin HCl 25 MG/mL Oral SolutionPSN11
1085918clindamycin 25 MG/ML Oral Solution [ClindaCure]SBD11
900424clindamycin 25 MG/ML Oral SolutionSCD11
1085918Clindacure (as clindamycin HCl) 25 MG/ML Oral SolutionSY11
1085918ClindaCure 25 MG per 1 ML Oral SolutionSY11
1085918ClindaCure 25 MG/ML Oral SolutionSY11
900424clindamycin (as clindamycin HCl) 25 MG/mL Oral SolutionSY11

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
CLINDAMYCIN Pharmacologic Class Indexing3Indexing - Pharmacologic Class20210811

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
a46239a7-5963-4008-8cbb-6b9000f497ebProduct name120250721
1426d8f8-b7d5-4053-8554-613df00c0d86Product name220250616
b382b4e1-6b48-45f6-bffc-e61b00b0ce19Product name320250317
d8f81258-db12-0761-46cc-8ff6e62e9302Product name420240422
b7b2fa42-1c77-d724-81f0-87da60a77e79Product name320240320
b27c7c65-51f2-a62f-e0e6-a26b3a0f8eb0Product name320230425
e3af9708-3004-7392-4046-5311eaa8bab5Product name320221128
ffb4bacf-f636-0f7d-0b0d-7a4b151243e3Product name920220928
b72227d6-0388-43bd-995b-b762d2754cd5Product name120220706
a92d22e0-3af4-f301-bc88-27ff030b0070Product name220220316
4a7d44fe-774d-404b-aad0-8a90fe78375aProduct name420211025
d12e2d7c-bd6b-45d4-94f9-6df8e1b8b27bProduct name320200203
ee5c6de5-d9cd-454f-b250-7b19e5cf2992Product name420190619
5ce6ce33-4f2b-3ce0-757d-e520013280cfProduct name520180719
b92a26f1-6926-4817-be73-e26ab4c2146fProduct name120170602
028d6c95-5012-6976-2075-dee0ae6fefe2Product name120140508
468b2c08-8adb-8d0f-8257-c6515a061424Product name120140508
8959fb29-d86f-c521-666a-b4cb22233594Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
50989-181-09ClindaCure12 in 1 CASELIQUID1211
50989-181-09ClindaCure1 in 1 CARTONLIQUID111

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
50989-181CLINDACURE (CLINAMYCIN HYDROCHLORIDE) LIQUID [VEDCO]112 package rows20241211_882cedd8-b1df-445a-b8cf-e9bdb1341b44.zip

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
CLINDAMYCIN HYDROCHLORIDEACTIVE INGREDIENTT20OQ1YN1W2
CLINDAMYCINACTIVE MOIETY3U02EL437C2

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 4 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
50989-18150989-181-09

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 1 matching rows.

Name, UNII, Kind table
NameUNIIKind
CLINDAMYCIN HYDROCHLORIDET20OQ1YN1WACTIM

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 4 · 78 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Clindamycin hydrochlorideCLINDAMYCIN HYDROCHLORIDEREMEDYREPACK INC.7f7fc73a-86e1-4d3e-8c83-1c74621e4af42026-07-31Boxed warning, Warnings, Adverse reactionsName fallback
generic name: CLINDAMYCIN HYDROCHLORIDE
Clindamycin hydrochlorideCLINDAMYCIN HYDROCHLORIDEHAWAII REPACK, INC.c6703df0-b41d-439f-8e0d-d30b3039b3f82026-07-18Boxed warning, Warnings, Adverse reactionsName fallback
generic name: CLINDAMYCIN HYDROCHLORIDE
Clindamycin HydrochlorideCLINDAMYCIN HYDROCHLORIDESt. Mary's Medical Park Pharmacy1dd9e6b0-bcf4-5bf4-e063-6394a90a10c22026-07-17Boxed warning, Warnings, Adverse reactionsName fallback
generic name: CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDECLINDAMYCIN HYDROCHLORIDEREMEDYREPACK INC.f4c4fce0-0472-45a3-b4c6-192d97ca18182026-07-17Boxed warning, Warnings, Adverse reactionsName fallback
generic name: CLINDAMYCIN HYDROCHLORIDE
Clindamycin HydrochlorideCLINDAMYCIN HYDROCHLORIDEMajor Pharmaceuticalsd53a66bf-fdbd-4a12-8d8c-4e3ab94e9ef52026-07-14Boxed warning, Warnings, Adverse reactionsName fallback
generic name: CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDECLINDAMYCIN HYDROCHLORIDEPD-Rx Pharmaceuticals, Inc.8e3c9cf6-ab39-4fb5-94e3-232880c477002026-07-08Boxed warning, Warnings, Adverse reactionsName fallback
generic name: CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDECLINDAMYCIN HYDROCHLORIDEPD-Rx Pharmaceuticals, Inc.de7001d1-8b83-4f8b-8e50-c076910214562026-07-08Boxed warning, Warnings, Adverse reactionsName fallback
generic name: CLINDAMYCIN HYDROCHLORIDE
Clindamycin hydrochlorideCLINDAMYCIN HYDROCHLORIDEPD-Rx Pharmaceuticals, Inc.fadc321a-2291-4268-936f-0743fdddbe7f2026-07-08Boxed warning, Warnings, Adverse reactionsName fallback
generic name: CLINDAMYCIN HYDROCHLORIDE
Clindamycin hydrochlorideCLINDAMYCIN HYDROCHLORIDEMajor Pharmaceuticalsf9e6ed50-ad03-4a9e-8760-8733e04a058c2026-06-29Boxed warning, Warnings, Adverse reactionsName fallback
generic name: CLINDAMYCIN HYDROCHLORIDE
Clindamycin hydrochlorideCLINDAMYCIN HYDROCHLORIDESun Pharmaceutical Industries, Inc.1dbd8448-c1e5-46df-8060-50ef823804452026-06-19Boxed warning, Warnings, Adverse reactionsName fallback
generic name: CLINDAMYCIN HYDROCHLORIDE
Clindamycin HydrochlorideCLINDAMYCIN HYDROCHLORIDEBryant Ranch Prepack47f76d99-2024-4531-a527-66c80deeeb372026-06-11Boxed warning, Warnings, Adverse reactionsName fallback
generic name: CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDECLINDAMYCIN HYDROCHLORIDEBryant Ranch Prepack5f6a85c5-dca3-49b1-a029-3818a41d49bf2026-06-08Boxed warning, Warnings, Adverse reactionsName fallback
generic name: CLINDAMYCIN HYDROCHLORIDE
Clindamycin HydrochlorideCLINDAMYCIN HYDROCHLORIDEST. MARY'S MEDICAL PARK PHARMACY1f1b9230-b8ef-b0e4-e063-6394a90afc472026-06-07Boxed warning, Warnings, Adverse reactionsName fallback
generic name: CLINDAMYCIN HYDROCHLORIDE
Clindamycin hydrochlorideCLINDAMYCIN HYDROCHLORIDEUnit Dose Solutions, Inc.535e7e17-d020-4aa6-e063-6294a90ae1142026-06-03Boxed warning, Warnings, Adverse reactionsName fallback
generic name: CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDECLINDAMYCIN HYDROCHLORIDESt. Mary's Medical Park Pharmacyafeb96ed-7c2e-72d3-e053-2995a90a4ed32026-06-01Boxed warning, Warnings, Adverse reactionsName fallback
generic name: CLINDAMYCIN HYDROCHLORIDE
Clindamycin hydrochlorideCLINDAMYCIN HYDROCHLORIDEGolden State Medical Supply, Inc.a69260bb-31b5-4f77-e053-2995a90a37e12026-05-28Boxed warning, Warnings, Adverse reactionsName fallback
generic name: CLINDAMYCIN HYDROCHLORIDE
Clindamycin HydrochlorideCLINDAMYCIN HYDROCHLORIDEBryant Ranch Prepacke4d91d51-b92e-4d3e-8379-f9463f4505372026-05-12Boxed warning, Warnings, Adverse reactionsName fallback
generic name: CLINDAMYCIN HYDROCHLORIDE
Clindamycin HydrochlorideCLINDAMYCIN HYDROCHLORIDEProficient Rx LPd1aa1e91-4ac8-40d1-9fc4-963e1c9c32782026-05-01Boxed warning, Warnings, Adverse reactionsName fallback
generic name: CLINDAMYCIN HYDROCHLORIDE
Clindamycin HydrochlorideCLINDAMYCIN HYDROCHLORIDECoupler LLC509a9bc3-0901-0874-e063-6294a90a88162026-04-29Boxed warning, Warnings, Adverse reactionsName fallback
generic name: CLINDAMYCIN HYDROCHLORIDE
clindamycin hydrochlorideCLINDAMYCIN HYDROCHLORIDEMylan Pharmaceuticals Inc.24595bb3-07ea-4d5f-9bb3-2c2332a1fc622026-04-28Boxed warning, Warnings, Adverse reactionsName fallback
generic name: CLINDAMYCIN HYDROCHLORIDE